Rafferty Asset Management
AVXL icon

Rafferty Asset Management’s Anavex Life Sciences AVXL Stock Holding History

Rafferty Asset Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-143,750
Closed -$441K – 1138
2026
Q1 		$441K Sell
143,750
-12,551
-8% -$54.4K ﹤0.01% 906
2025
Q4 		$556K Buy
156,301
+47,873
+44% +$293K ﹤0.01% 892
2025
Q3 		$965K Buy
108,428
+16,284
+18% +$165K ﹤0.01% 800
2025
Q2 		$850K Sell
92,144
-35,310
-28% -$301K ﹤0.01% 791
2025
Q1 		$1.09M Buy
127,454
+52,853
+71% +$499K ﹤0.01% 725
2024
Q4 		$801K Sell
74,601
-64,985
-47% -$500K ﹤0.01% 829
2024
Q3 		$793K Sell
139,586
-84,728
-38% -$489K ﹤0.01% 845
2024
Q2 		$947K Sell
224,314
-445,631
-67% -$1.8M ﹤0.01% 833
2024
Q1 		$3.41M Buy
669,945
+437,914
+189% +$2.46M 0.01% 546
2023
Q4 		$2.16M Sell
232,031
-38,757
-14% -$267K 0.01% 656
2023
Q3 		$1.77M Sell
270,788
-79,874
-23% -$636K 0.01% 647
2023
Q2 		$2.85M Sell
350,662
-114,593
-25% -$982K 0.02% 545
2023
Q1 		$3.99M Buy
465,255
+501
+0.1% +$5K 0.03% 433
2022
Q4 		$4.3M Buy
464,754
+189,808
+69% +$2.03M 0.04% 411
2022
Q3 		$2.84M Buy
274,946
+107,130
+64% +$1.13M 0.03% 431
2022
Q2 		$1.68M Sell
167,816
-200,283
-54% -$1.9M 0.02% 516
2022
Q1 		$4.53M Buy
368,099
+125,185
+52% +$1.54M 0.03% 412
2021
Q4 		$4.21M Buy
242,914
+76,282
+46% +$1.45M 0.02% 451
2021
Q3 		$2.99M Sell
166,632
-1,657
-1% -$33K 0.02% 479
2021
Q2 		$3.85M Buy
168,289
+49,312
+41% +$730K 0.02% 414
2021
Q1 		$1.78M Buy
+118,977
New +$1.3M 0.01% 655

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rafferty Asset Management's AVXL Position: Q2 2026 in Review

Rafferty Asset Management sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 143,750 shares — an estimated $441K sold.

Rafferty Asset Management first reported a position in AVXL in Q1 2021 and held it in 21 quarters. The position peaked at $4.53M in Q1 2022. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Rafferty Asset Management reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 143,750 Anavex Life Sciences shares in Q2 2026, an estimated $441K.
  • Rafferty Asset Management first reported a position in Anavex Life Sciences in Q1 2021 and held it in 21 quarters.
  • Rafferty Asset Management's Anavex Life Sciences position peaked at $4.53M in Q1 2022.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.